Home
RNA Therapeutics (Virtual Conference)
10 February - 11 February 2021

Post event on demand access to recorded presentations will be available to all attendees 5 working days from the end date of the event.

RNA Therapeutics (Virtual Conference)

SAE Media Group is proud to announce the 12th Annual RNA Therapeutics Virtual Conference taking place on 10 - 11 February 2021


RNA therapeutics is a rapidly expanding industry with increasingly growing potential for immunotherapy personalised medicines, and treatment of genetic, infectious and chronic diseases. This is reflected with the value of the global antisense & RNA therapeutics market expected to reach USD 1.81 billion by 2025, growing at a CAGR of 7.5%. Furthermore, the recent advent of CRISPR, an RNA-guided gene-editing technology, as well as new strides in the delivery of messenger RNA transcribed in vitro, have triggered a major expansion of the RNA-therapeutics field.

The 2021 conference is set to explore the latest developments in RNA delivery agents and RNA-based therapeutics with the latest case studies on advanced mRNA technologies, oligonucleotide delivery, therapeutic applications and future trends and innovations.

Join us in February 2021, as SAE Media Group’s 12th annual RNA Therapeutics Conference brings together industry experts from leading RNA therapeutics companies to gain an expert and holistic view on the latest developments in the industry, upcoming regulatory updates and industry implications.
 

FEATURED SPEAKERS

Alexey Wolfson

Alexey Wolfson

CEO, Advirna
Andre  Müller-York

Andre Müller-York

Senior Medical Affairs Director , Sarepta Therapeutics Germany GmbH
Arpan Desai

Arpan Desai

Team Leader, Advanced Drug Delivery, Pharmaceutical Sciences, Astrazeneca
Barry Ticho

Barry Ticho

Chief Medical Officer, Stoke Therapeutics
Cristina Reschke

Cristina Reschke

Lecturer, School of Pharmacy and Biomolecular Sciences , Royal College of Surgeons in Ireland
David Evans

David Evans

Chief Scientific Officer, Sirnaomics, Inc
Dong-Ki Lee

Dong-Ki Lee

CEO, OilX Pharmaceuticals
Ekkehard Leberer

Ekkehard Leberer

Senior Director, Global Alliance Management, Sanofi
Fengmei Pi

Fengmei Pi

General Manager and Director of R&D, ExonanoRNA
Giulietta Maruggi

Giulietta Maruggi

Head, Vector Biology, GSK Vaccines
Heidi M Berven

Heidi M Berven

Partner, Co-Leader, Patent Practice Group, Honigman
Heinrich Haas

Heinrich Haas

Vice President Formulation and Drug Delivery , BioNTech
Jennifer Pluim

Jennifer Pluim

Vice President Medical Afffairs, ProQR
Kevin Lance

Kevin Lance

Marketing Manager, Unchained Labs
Loic Roux

Loic Roux

Head of Chemistry, NATA
Maria Luisa Pineda

Maria Luisa Pineda

CEO and Co-founder, Envisagenics
Matthew J McBride

Matthew J McBride

Director of IP Search, CAS
Michael Mulqueen

Michael Mulqueen

VP Business Development, eTheRNA Immunotherapies
Morag Rose Hunter

Morag Rose Hunter

Senior Scientist, AstraZeneca
Priya Karmali

Priya Karmali

Vice President, Technology Innovation and Development, Arcturus Therapeutics
Ruchi Shah

Ruchi Shah

Senior Research Engineer, New Therapeutics Modalities, Eli Lilly and Company
Shalini Andersson

Shalini Andersson

Chief Scientist New Therapeutic Modalities and Head of Oligonucleotide Discovery, AstraZeneca
Thomas Thum

Thomas Thum

Director, Institute of Molecular and Translational Therapeutic Strategies , Hannover Medical School
Tim Ellis

Tim Ellis

Programme Manager, Translational Research, Medical Research Council
Troels Koch

Troels Koch

CEO & Founder, Aqiventa
Wigard Kloosterman

Wigard Kloosterman

CSO, Frame Therapeutics

Alexey Wolfson

CEO, Advirna
Alexey Wolfson

Alexey has completed his Masters degree in Molecular Biology at Moscow State University (Russia) following which he obtained a PhD in Biochemistry from A.N.Bakh Institute of Biochemistry (Moscow, Russia). After completing postdoctoral training in IBMC (Strasbourg, France) and Temple University he joined University of Colorado at Boulder as research assistant professor, where he worked on enzymology and biology of tRNAs and other small RNAs. In 2008 he moved to UMass Medical school as a research assistant professor to work on miRNA and in 2009 founded Advirna – a biotech company developing oligonucleotide delivery technologies, where he serves as CEO and CSO. His work on different aspects of RNA biology and biochemistry has been published in over 50 peer-reviewed papers, including Science, PNAS, NAR and Molecular Therapy. His current work is focused on making advanced nucleic acids delivery technologies available to a broad scientific community.

Anders Hogset

Chief Scientific Officer, PCI Biotech AS
Anders Hogset

Anders Høgset is Chief Scientific Officer (CSO) in PCI Biotech AS in Oslo since April 2001, and he was also CEO in the company from 2004 to 2008. He holds a PhD in biochemistry from the University of Oslo. Earlier employments include: senior scientist at The Norwegian Radium Hospital in Oslo, senior scientist and project manager at Nycomed (now GE Healthcare), scientist at the University of Oslo. Høgset is co-author on more than 90 scientific publications and inventor on more than 20 international patents and patent applications.

Andre Müller-York

Senior Medical Affairs Director , Sarepta Therapeutics Germany GmbH
Andre  Müller-York

Dr. André Müller-York obtained his MD from the Medical School of the University of Hamburg (Germany) and his board certification in nuclear medicine from the Charité at the University of Berlin. He joined the pharmaceutical industry at Amersham Health (now GE Healthcare) leading the clinical development of a cardiac MRI contrast media in EU and US. Later on, André supported several international companies for medical affairs in various indications, e.g. virology and neurology. Focused on orphan drugs and neuromuscular diseases during the last five years, he is now representing the medical affairs department of Sarepta Therapeutics (HQ: Cambridge, MA, USA) as a Sr. Medical Director in DACH, CEE and Russia. Starting with the development of phosphorodiamidate morpholino oligomers (PMOs), a subclass of antisense oligonucleotides (ASOs) for exon-skipping in Duchenne Muscular Dystrophy, the company is now also focusing on the development of AAV-based gene therapies for several neuromuscular diseases.

Arpan Desai

Team Leader, Advanced Drug Delivery, Pharmaceutical Sciences, Astrazeneca
Arpan Desai

Arpan completed his first degree in Biotechnology at the University of Edinburgh, following which he obtained a PhD from the AZ/University of Nottingham Doctoral Training Centre in Targeted Therapeutics, where he studied the uptake and intracellular trafficking pathways of polymeric nanoparticles using pH-based nanosensors. He joined AZ in 2013 where he has worked primarily in the field of nucleic acid delivery. He has played a leading role in AZs formulation and delivery development activities for therapeutic nucleic acids with a focus on understanding cellular delivery mechanisms of mRNA using non-viral delivery vehicles. He has played a leading role in a number AZs collaborations to develop nucleic acid-based therapeutics including Moderna Therapeutics (mRNA), Ionis (ASOs) and Regulus (anti-miRs). More recently, he has established AZs Nucleic Acid Drug Delivery (NDD) team. This is a global discovery research focused group with the ultimate mission of apply delivery science to help advance nucleic acid based therapies into the clinic.

Barry Ticho

Chief Medical Officer, Stoke Therapeutics
Barry Ticho

As Chief Medical Officer Dr. Ticho is responsible for Stoke’s efforts to develop first-in-class RNA based disease-modifying medicines to treat severe neurologic genetic diseases. Prior to joining Stoke Barry was Head of R&D for Cardiovascular and Metabolic Diseases at Moderna Therapeutics. He was previously Head of External R&D Innovation for Cardiovascular and Metabolic Diseases at Pfizer. Prior to that he was Vice President of Clinical Development at Biogen where he led clinical development for the Tysabri program for MS and led the aducanumab program for Alzheimer’s Disease. Barry obtained his M.D. and Ph.D. degrees from the University of Chicago and completed Pediatrics training at Northwestern University and a Cardiology fellowship at Children’s Hospital in Boston. He was on clinical staff at Harvard Medical School and Massachusetts General Hospital.

Cristina Reschke

Lecturer, School of Pharmacy and Biomolecular Sciences , Royal College of Surgeons in Ireland
Cristina Reschke

Cristina Reschke is Lecturer in the School of Pharmacy and Biomolecular Sciences at the Royal College of Surgeons in Ireland. She trained as a Pharmacist and went on to obtain an M.Sc. (2010) and Ph.D. (2013) in Pharmacology from the Federal University of Santa Maria in Brazil, studying the effects of neuroinflammation in epilepsy. Reschke then moved to Ireland for post-doctoral training, joining Prof. David Henshall’s group to advance discoveries on the role of microRNAs in experimental and human epilepsy. Her work has been internationally awarded, including the prestigious Harinarayan Young Neuroscientist Award 2015 (by International League Against Epilepsy; ILAE), the Grass Young Investigator Award 2017 (by American Epilepsy Society; AES). Reschke is a Funded Investigator of the FutureNeuro Research Centre (www.futureneurocentre.ie) and her most recent research interest is understanding the influence of circadian rhythm regulation in epilepsy.

David Evans

Chief Scientific Officer, Sirnaomics, Inc
David Evans

Dr. David Evans obtained his BSc and PhD from Imperial College, London. His focus has been building scientific research teams focused on target validation and drug discovery – primarily in Oncology. David previously worked in the Boston area at Millennium Pharmaceuticals and Serono Pharmaceuticals and has over 15 years’ experience in the RNAi field. David cofounded Sirnaomics in 2008 to develop siRNA therapeutics and is CSO for the company. Sirnaomics has its HQ in Gaithersburg, Maryland and labs in Suzhou and Guangzhou, China. Sirnaomics is using its Histidine Lysine branched polypeptide nanoparticle system to deliver siRNAs to treat cancer and fibrotic diseases – with products in Phase2 trials. The company is also developing targeted delivery of novel siRNA constructs to further address oncology indications.

Dong-Ki Lee

CEO, OilX Pharmaceuticals
Dong-Ki Lee

Prof. Dong-ki Lee received B. S. in Chemistry from Korea Advanced Institute of Science and Technology (KAIST) in 1993, and Ph. D. in Biochemistry from Cornell University in 1999. After post-doctoral training in Pohang University of Science and Technology (POSTECH), Toolgen Inc., and KAIST, he joined POSTECH as an assistant professor in 2004. In 2008, He moved to Sungkyunkwan University and is a full professor of Chemistry since 2012. In 2008, Prof. Lee was selected as the principal investigator of the Global Research Laboratory program, funded by Korean government, to develop novel RNAi medicine. He is currently serving as the Asian editor of “Nucleic Acid Therapeutics” and a editorial board member of "Molecular Therapy: Nucleic Acids". His work on novel siRNA structures, nucleic acid aptamers, and eukaryotic gene regulation has been published as over 80 papers including prestigious journals such as Nature, Cell, PNAS, and Molecular Therapy. In 2010, he founded OliX Pharmaceuticals, a publicly traded RNAi therapeutics company, and serves as Chief Executive Officer.

Ekkehard Leberer

Senior Director, Global Alliance Management, Sanofi
Ekkehard Leberer

Dr. Leberer received his Ph.D. in Biology at the University of Konstanz, Germany (1986), and conducted post-doctoral training in molecular biology at the Banting and Best Institute of the University of Toronto, Canada. He then obtained the Habilitation for Professor of Biochemistry at the University of Konstanz, Germany (1992). From 1989-1998, he served as Senior Research Officer in genetics and genomics at the Biotechnology Research Institute, National Research Council of Canada, Montreal. He was also Adjunct Professor at McGill University, Montreal.
Since joining Hoechst Marion Roussel in 1998, Dr. Leberer carried out various managing roles in this company, Sanofi’s predecessor companies and Sanofi itself, including responsibilities in functional genomics, biological sciences and external innovation for oligonucleotide-based therapeutics. Since 2012, he is Global Alliance Manager for R&D at Sanofi, Frankfurt. In addition, from 2012-2018, he has been the Scientific Managing Director of the Innovative Medicines Initiative COMPACT Consortium on the delivery of biopharmaceuticals across biological barriers and cellular membranes (www.compact-research.org), Brussels. He serves as a member in Scientific Advisory Boards of several biotechnology companies, and he is the Head of the Supervisory Board of BioM, Munich.
His research has focused on the molecular mechanisms of signal transduction and the role of signalling molecules in human diseases. He is the co-discoverer of the p21 activated protein kinase (PAK) family of cell signalling proteins and of novel virulence-inducing genes in pathogenic fungi. He is co-author of more than 60 publications in prestigious peer-reviewed journals including Nature and Science.
 

Fengmei Pi

General Manager and Director of R&D, ExonanoRNA
Fengmei Pi

Fengmei Pi is currently the General Manager and Director of R&D for ExonanoRNA LLC. She got her PhD in pharmaceutical Science from University of Kentucky. She is an expert in RNA nanotechnology for cancer treatment and authored more than 20 publications in high impact journals, co-inventor of the issued core technology patents related to RNA nanoparticles decorated exosomes for targeted delivery of siRNA. She has 10+ pharmaceutical development experience from GSK, Daewoong Pharmaceutical and Nanobio Delivery Pharmaceutical. Her recent research focus on the Chemistry, Manufacture and Quality Control, and pre-clinical in vitro and in vivo test of RNA and modified oligos, RNA nanoparticles, exosomes for IND direction.

Giulietta Maruggi

Head, Vector Biology, GSK Vaccines
Giulietta Maruggi

Dr. Giulietta Maruggi, Ph.D. is leading the Vector Biology team at GSK Vaccines, US bringing with her over 10 years of research in engineering and developing viral vectors (alphavirus, adenovirus, retro- and lentivirus, adeno-associated virus) for vaccine and gene therapy applications in both academia and industry. She completed her PhD at the Centre for Regenerative Medicine at the University of Modena in 2008 working on development of gene therapy for skin and hematopoietic genetic diseases. She completed her post-doctoral Training in vaccine development at Novartis Vaccines, Cambridge, MA with a specific focus on enhancing the potency of Self-amplifying mRNA (SAM) vaccines by exploring their mechanism of actions. At Novartis vaccines first and GSK vaccines later, she successfully managed multi-disciplinary collaborative efforts to characterize vaccine candidates (including viral and bacterial vaccines-based RNA and non-replicating live viral vectors) in vitro and in vivo. She is currently the preclinical leader for the SAM vaccine platform technology in GSK Vaccines. In this role she is leading a cross-functional matrix team to develop and understand mechanism of action of SAM vaccines.

Heidi M Berven

Partner, Co-Leader, Patent Practice Group, Honigman
Heidi M Berven

Heidi M. Berven, Ph.D. is partner at Honigman and a co-leader of the Patent practice group at the firm. She is a seasoned attorney with more than 20 years of experience. As patent counsel for both large and small companies, she honed her skills in drafting and prosecuting chemistry and pharmaceutical patent applications and in providing IP support for negotiations ranging from single-compound licensing transactions to whole company acquisitions.

Dr. Berven’s practice routinely includes patent preparation and prosecution in the U.S. and globally; life cycle management of global patent portfolios; competitor intelligence; IP support for licensing negotiations; freedom-to-operate and patentability reviews; Patent Term Adjustment maximization by action before the USPTO and federal courts; and Orange Book listings and Patent Term Extension maximization for approved drug products. In her free time, Dr. Berven enjoys outdoor activities and traveling.
 

Heinrich Haas

Vice President Formulation and Drug Delivery , BioNTech
Heinrich Haas

Heinrich has more than 20 years of experience in academic research and industrial pharmaceutical development. His focus is on development for advanced drug delivery systems. After he received his Ph.D. in physical chemistry, he researched lipid membranes and organized biomolecular systems. He was responsible for projects in different biopharmaceutical companies for research and development of diagnostic and therapeutic carrier systems. Joining BioNTech in 2010, he helped build the formulation development and analytics unit, which develops formulations for delivery of RNA and small molecules.

Jennifer Pluim

Vice President Medical Afffairs, ProQR
Jennifer Pluim

Jennifer is Vice President, Medical Affairs at ProQR, a biotechnology company dedicated to changing lives by developing RNA therapies for rare genetic diseases, with a focused drug development on a group of blinding disorders affecting the retina, called inherited retinal diseases. Jennifer has over 25 years’ experience in the pharmaceutical industry, with extensive knowledge in clinical operations, project management and medical affairs. Her experience spans several therapeutic areas, including infectious diseases, respiratory critical care, cardiovascular disease, oncology and ophthalmology. Jennifer earned a B.S. in Microbiology with certification as a Medical Technologist and an MBA from The Pennsylvania State University USA.

Kevin Lance

Marketing Manager, Unchained Labs
Kevin Lance

Kevin Lance is the Marketing Manager covering analytical instruments globally at Unchained Labs. He has served in various leadership roles and technical roles at Unchained Labs. He has published works and secured patents in the fields of sustained antibody delivery and nanotechnology, and has worked as a consultant to advance the development of biologics for several major biopharmaceutical companies. He earned his Ph.D. in Bioengineering from the joint UC Berkeley – UCSF Bioengineering Graduate Program.

Kirsty Wydenbach

Deputy Unit Manager/Senior Medical Assessor, MHRA
Kirsty Wydenbach

Dr Kirsty Wydenbach is a Senior Medical Assessor and the Deputy Unit Manager in the Clinical Trials Unit, having joined the MHRA in 2009. She has been involved in the UK regulation of clinical trials across all therapy areas and all phases of development, including ATMPs and many first-in-man studies. She has also been involved in European discussions aiming to establish an EU harmonised approach to clinical trials, particularly for Developmental Safety Update Reports (DSURs) and Reference Safety Information (RSI). She was also an EMA expert for the update of the First-in-Human guideline. Other recent work has included collaboration with external industry groups and regulators regarding adaptive and novel trial designs: she is leading on this aspect for the MHRA in order to implement that aspect of the Life Sciences Industrial Strategy, and was a contributor to the EU CTFG “Recommendation Paper on the Initiation and Conduct of Complex Clinical Trials”. More recently Kirsty has overseen the clinical trial work for COVID-19 and provided regulatory expertise on vaccines both within MHRA but also as part of the government Vaccine Taskforce.

Loic Roux

Head of Chemistry, NATA
Loic Roux

Dr. Loïc Roux received his Ph.D in Medicinal Chemistry from Aix-Marseille University in France. His work focused on the development of new nucleotides pro-drugs against HIV focusing on the phosphorus chemistry. He joined Prof. Khvorova's lab (UMass Med School, MA, USA) in 2018 working on the stabilization and delivery of fully chemically modified oligonucleotides for neurodegenerative diseases and then Prof. Wood's lab (University of Oxford, UK) working on peptide-oligonucleotides conjugates for muscular degenerative diseases. After a position as principal scientist at PepGen Limited promoting a peptide delivery platform for nucleic acid delivery, he is currently the Head of Chemistry of NATA, a new UKRI initiative aiming to promote the development of nucleic acid therapeutics.

Maria Luisa Pineda

CEO and Co-founder, Envisagenics
Maria Luisa Pineda

Dr. Maria Luisa Pineda is the co-founder and CEO of Envisagenics, Inc. a biotech spinout of Cold Spring Harbor Laboratory that integrates proprietary machine learning algorithms, high performance computing, and RNA-splicing analytics to identify disease-specific splicing variants as therapeutic targets. Envisagenics has leveraged its SpliceCore® software platform for therapeutic development with its first pipeline of assets in triple negative breast cancer. In April, Envisagenics has announced an oncology partnership leveraging SpliceCore with The Lung Cancer Initiative at Johnson & Johnson.

Matthew J McBride

Director of IP Search, CAS
Matthew J McBride

Matt is Director IP Search at CAS, where he manages all aspects of IP service development and sales and works regularly with CAS customers to develop effective strategies for delivering high-quality IP and scientific information. He became a member of the IP Services team in 2010, after spending six years as a Senior Application Specialist providing technical training for the STN and SciFinder software platforms to CAS customers.
He holds a Master of Science degree in plant pathology from the University of Minnesota and a Bachelor of Science degree in molecular biology from Purdue University. In addition to his research experience at CAS, Matt was an information consultant with Thomson Reuters and a biologist at Rohm and Haas.
Matt is a member of the Patent Information Users Group (PIUG) and the American Chemical Society (ACS).
 

Michael Mulqueen

VP Business Development, eTheRNA Immunotherapies
Michael Mulqueen

Michael started his career with Roche as part of the business development department with a strong focus on in-licensing and alliance management. He left Roche to set up Synosia Therapeutics AG. From this point on, he worked with a number of European biotech companies with a focus on out-licensing and partnering. Latterly, he was VP for BD and Licensing with Silence Therapeutics in the RNAi field.

Morag Rose Hunter

Senior Scientist, AstraZeneca
Morag Rose Hunter

Morag Rose Hunter is a cell biologist with a special interest in high content assays and nucleic acid therapeutics. After her PhD in Pharmacology at the University of Auckland, New Zealand, Morag took up a postdoctoral position at the University of Cambridge, UK, specialising in the endosomal system and intracellular trafficking. Morag joined AstraZeneca in 2018, working with both the Nucleic Acid Drug Delivery (Pharmaceutical Sciences) and Functional Genomics (Discovery Sciences) teams. She utilises imaging data from high-throughput screening to investigate how the efficacy of RNA therapeutics is related to a cell’s endosomal activity.

Morag Rose Hunter

Senior Scientist, AstraZeneca
Morag Rose Hunter

Priya Karmali

Vice President, Technology Innovation and Development, Arcturus Therapeutics
Priya Karmali

Priya Karmali is Vice President of Technology Innovation and Development at Arcturus Therapeutics. In her current position, she is responsible for research and development efforts for LUNAR® technology, Arcturus’ lipid mediated nucleic acid delivery system. Priya has over 20 years of experience in the field of lipid mediated nucleic acid delivery from discovery to development and has led drug product development of multiple RNA based therapeutics that are currently in various phases of clinical trials. Since joining Arcturus, Priya has led pharmaceutical development efforts for Arcturus’ clinical candidates, LUNAR-OTC (OTC mRNA replacement therapy) and LUNAR-COV19 (COVID-19 Vaccine) and continues to drive similar efforts for upcoming programs in rare diseases and vaccines. Prior to Arcturus, in her role as head of formulation development at Regulus Therapeutics, Priya led drug product development of multiple miRNA candidates currently in clinical trials. Prior to Regulus, Priya held positions of increasing responsibility at Nitto Denko (currently Nitto Biopharma) where she led formulation development efforts for ND-L02-s0201, a Vitamin A targeted siRNA lipid nanoparticle that completed Phase 1b/2 for extensive hepatic fibrosis and currently in Phase 2 evaluation for Idiopathic Pulmonary. Priya received her PhD in Chemistry from the Indian Institute of Chemical Technology, India where her doctoral research was focused on development of novel liposomal nucleic acid delivery systems for use in non-viral gene therapy and DNA vaccination. She pursued her postdoctoral research at Sanford-Burnham-Preby’s-Medical Discovery Institute, La Jolla, CA focusing on developing targeted nanoparticles for drug delivery. Priya is an author and co-inventor on over 40 publications and patents.

Ruchi Shah

Senior Research Engineer, New Therapeutics Modalities, Eli Lilly and Company
Ruchi Shah

Dr. Ruchi Shah received her M.S. and Ph.D in Pharmaceutical Sciences from Northeastern University in Boston, MA, USA. Her graduate work focused on development of lipid-based adjuvants for subunit vaccines in collaboration with the vaccines business of GlaxoSmithKline. Dr. Shah has led formulation and development activities of lipid-based delivery systems for mRNA and CRISPR Cas9 for both vaccines and therapeutics at GlaxoSmithKline Vaccines, Intellia Therapeutics and Moderna Therapeutics. Currently in her role at Eli Lilly and Company, she is a Senior Research Engineer in the New Therapeutics Modalities group to accelerate and develop novel therapies for unmet medical needs.

Shalini Andersson

Chief Scientist New Therapeutic Modalities and Head of Oligonucleotide Discovery, AstraZeneca
Shalini Andersson

Shalini is currently Chief Scientist New Modalities and Head of Oligonucleotide Discovery in BioPharmaceuticals R&D. Shalini has also the strategic responsibility for explorative activities and build of capabilities in the new therapeutic modalities area.
Shalini has broad experience in Pharmaceutical research as well as of strategic and management roles and drives several collaborations with external partners and academic groups across the globe.
Prior to this role, Shalini held several leadership roles within Cardiovascular, renal and metabolism.

Shalini received her PhD in 1989 at the University of Linköping, Sweden and has held various research and teaching positions at the University of Linköping prior to moving to industry. She is the author or co-author of over 45 peer reviewed articles, 2 book chapters and 4 patents.
 

Thomas Thum

Director, Institute of Molecular and Translational Therapeutic Strategies , Hannover Medical School
Thomas Thum

Thomas Thum studied medicine in Hannover, with state examination in 2001 and board examination for internal medicine/cardiology in 2009/2010. He received his PhD at the Imperial College, London (2008). He is a full professor and director of the Institute of Molecular and Translational Therapeutic Strategies at the Hannover Medical School (MHH), Visiting Professor at the Imperial College, and director of MHH’s Center for Translational Regenerative Medicine. He (co-) authors > 350 publications and is a distinguished reviewer, board member, patent holder, and founder.

Tim Ellis

Programme Manager, Translational Research, Medical Research Council
Tim Ellis

Dr. Tim Ellis received his Ph.D in biomedical material science from Imperial College London, developing nanoparticulate therapies for the aerosolised treatment of drug-resistant TB. Having supported the Government Chief Scientific Advisor, Patrick Vallance, at the Government Office for Science, followed by a number of policy advisor roles in the Department of Health’s Global and Public Health Directorate, he now works within the MRC’s translational research team managing the UK Nucleic Acid Therapy Accelerator (NATA).

Troels Koch

CEO & Founder, Aqiventa
Troels Koch

Troels Koch (TK) has 20 years’ experience in the international life science and biopharmaceutical industry. Founder of several biotech companies of which Exiqon A/S and Santaris Pharma A/S are the most commonly known. Santaris Pharma A/S was successfully exited in August 2014 – acquired by Roche, and Exiqon A/S was acquired in 2016 by Qiagen. TK has been positioned in company management teams and taken part in all aspects of executive decision making: Company strategy, VC fundraising, deal makings, partnering, IP strategy & prosecution, drug discovery and R&D. TK pioneered LNA therapeutics and has been responsible for keeping LNA antisense science and technology at an international lead position. He has worked with RNA therapeutics for 20 years and taken an active role in all steps of oligonucleotide drug discovery and development. TK has built R&D organizations up to 75 co-workers, held 100+ invited presentations at international conferences and is author of 80+ peer reviewed publications.

Wigard Kloosterman

CSO, Frame Therapeutics
Wigard Kloosterman

Dr. Wigard Kloosterman is Chief Scientific Officer at Frame Therapeutics, a biotech start-up aimed at revolutionising cancer immunotherapy based on Framome neoantigen detection technology. Dr. Kloosterman is an expert is cancer genomics and bioinformatics. He has previously served as a group leader at the University Medical Center in Utrecht (Netherlands), where he focused on understanding cancer genomes through advanced sequencing technologies. Besides his role at Frame Therapeutics, Dr. Kloosterman founded Cyclomics, a company focused on early cancer detection using single-molecule sequencing technology.

sponsors

Conference agenda

clock

9:00

Chair's Opening Remarks

Heinrich Haas, Vice President Formulation and Drug Delivery , BioNTech

Shalini Andersson, Chief Scientist New Therapeutic Modalities and Head of Oligonucleotide Discovery, AstraZeneca

clock

9:10

Approaches for Next Generation Lipid Nanoparticle Technologies for RNA Delivery

Heinrich Haas, Vice President Formulation and Drug Delivery , BioNTech

  • Lipid nanoparticles comprising ionizable lipids are versatile delivery systems for therapeutic application of RNA
  • Although having been already successfully translated into clinical practice, there is need for further development of this technology in order to allow its application in a wider range of therapeutic settings
  • Here we present approaches for engineering m-RNA LNPs with improved biological activity and safety
  • The systems may be promising for development of next generation potent and safe RNA therapeutics for clinical translation
  • clock

    9:40

    Update on the regulatory environment for clinical trials in the UK

    Kirsty Wydenbach, Deputy Unit Manager/Senior Medical Assessor, MHRA

  • Changes to the regulation of clinical trials in the UK since January 2021
  • Novel clinical trials and MHRA advice services
  • The future of the MHRA
  • clock

    10:10

    Advancing technologies in oligonucleotide delivery - case studies

    Michael Mulqueen, VP Business Development, eTheRNA Immunotherapies

  • Lipid nanoparticles for mRNA delivery to lymphoid organs
  • Oncolysis and tumour microenvironment modulating technology
  • Immunostimulation technology to boost the immune response through the dendritic cell pathway
  • Applications for novel oligonucleotide delivery approaches
  • clock

    10:40

    Morning Break and Virtual Exhibitor Hall Open

    clock

    11:10

    Advances in the biological understanding of lipid nanoparticle delivery to different cell types

    Morag Rose Hunter, Senior Scientist, AstraZeneca

  • A new machine learning based biological profiling approach to accelerate LNP optimisation
  • Application of biological profiling to optimise LNPs for liver delivery
  • Using biological profiling to understand intracellular delivery to different tumour cell types
  • clock

    11:40

    Oligonucleotides as a therapeutic option for Duchenne Muscular Dystrophy (DMD)

    Andre Müller-York, Senior Medical Affairs Director , Sarepta Therapeutics Germany GmbH

  • Background for the oligonucleotides PMOs / PPMOs and the MoA for RNA-exon skipping
  • I.v. PMOs / PPMOs for RNA-exon skipping in DMD
  • Clinical results for the PMOs / PPMOs from the Sarepta pipeline in DMD
  • clock

    12:10

    Photochemical internalisation (PCI) – enhanced and site-directed oligonucleotide and mRNA delivery by light-induced endosomal release

    Anders Hogset, Chief Scientific Officer, PCI Biotech AS

  • PCI can strongly enhance both vehicle-mediated- and naked RNA delivery
  • In vivo, PCI enhances the delivery of naked mRNA up to 50 times as compared to mRNA alone
  • For intratumoural mRNA delivery, PCI with naked mRNA compares favourably to delivery by LNPs 
  • PCI site-directs delivery by illumination
  • clock

    12:50

    Evolution, challenges and potential of RNA Therapeutics

    Ruchi Shah, Senior Research Engineer, New Therapeutics Modalities, Eli Lilly and Company

  • Background on RNA Therapeutics –what it encompasses, current status and pipeline
  • Challenges surrounding development of RNA Therapeutics
  • Promising future of RNA therapeutics
  • clock

    13:20

    Networking Break and Virtual Exhibitor Hall Open

    clock

    14:20

    Novel Therapies for Inherited Retinal Diseases

    Jennifer Pluim, Vice President Medical Afffairs, ProQR

  • An overview of ProQR’s RNA therapies platform
  • Sepofarsen (QR-110) for Leber’s Congenital Amaurosis (LCA10)
  • QR-421a for Usher syndrome Exon 13
  • QR-1123 for P23H autosomal dominant RP
  • QR-504a for Fuchs Endothelial Corneal Dystrophy
  • clock

    14:50

    Moving cardiovascular noncoding RNA therapeutics towards clinical reality

    Thomas Thum, Director, Institute of Molecular and Translational Therapeutic Strategies , Hannover Medical School

  • Innovative approaches to discover noncoding RNAs in cardiovascular disease
  • Testing noncoding RNAs in large animal models
  • Design of adaptive clinical studies using noncoding RNA modulators
     
  • clock

    15:20

    RNA immunotherapies: developing cancer vaccines against immunogenic neoantigens

    Wigard Kloosterman, CSO, Frame Therapeutics

  • A collaboration with the aim to develop a new generation of cancer vaccines via RNA
  • New developments in immunology have made immunotherapy of cancer a new treatment option
  • An overview of the technology and potential for further oncology therapeutics
  • clock

    15:50

    Afternoon Break and Virtual Exhibitor Hall Open

    clock

    16:20

    Self-amplifying mRNA (SAM) vaccines

    Giulietta Maruggi, Head, Vector Biology, GSK Vaccines

  • Overview the principal and preclinical program of the GSK self-amplifying RNA program, illustrated by specific examples
  • Update the progress on its technical development
  • Potentially discuss the clinical POC of the platform
  • clock

    16:50

    Self-deliverable RNAi ex-vivo and in-vivo

  • Exploring the sdRNAi technology and its use for RNA interference
  • How can siRNAs be modified to achieve self-delivery?
  • Discussing what is required for the efficient delivery of RNAi into all cell types ex-vivo and to certain organs in vivo
  • Which cell types can self-deliverable RNAis target?
  • Alexey Wolfson, CEO, Advirna

    clock

    17:20

    Get the skinny on LNPs with Stunner and Big Tuna

    Kevin Lance, Marketing Manager, Unchained Labs

  • How Big Tuna automates ethanol clean-up & buffer prep
  • High-throughput sizing and total RNA quant for LNP samples on Stunner
  • High accurate and precise nucleic acid quant on 2 uL samples
  • clock

    18:00

    Delivery of Novel siRNA constructs for treating cancer

    David Evans, Chief Scientific Officer, Sirnaomics, Inc

  • Creating novel siRNA constructs for cancer treatment
  • Addressing the challenges of cell-specific delivery: how to get size and efficacy right?
  • Choosing the appropriate delivery system
  • Steps taken towards validation of novel constructs
  • clock

    18:30

    Chair’s Closing Remarks

    Heinrich Haas, Vice President Formulation and Drug Delivery , BioNTech

    Shalini Andersson, Chief Scientist New Therapeutic Modalities and Head of Oligonucleotide Discovery, AstraZeneca

    clock

    9:00

    Chair's Opening Remarks

    Heinrich Haas, Vice President Formulation and Drug Delivery , BioNTech

    Shalini Andersson, Chief Scientist New Therapeutic Modalities and Head of Oligonucleotide Discovery, AstraZeneca

    clock

    9:10

    Targeted Nucleic Acid therapeutics

    Shalini Andersson, Chief Scientist New Therapeutic Modalities and Head of Oligonucleotide Discovery, AstraZeneca

  • Concept of targeted delivery of nucleic acid therapeutics
  • Different targeting approaches and impact on efficacy and therapeutic window
  • Utility of targeted delivery in pre-clinical and clinical drug development
  • Future direction
  • clock

    9:40

    Therapeutic development using chemically modified asymmetric small interfering RNAs

    Dong-Ki Lee, CEO, OilX Pharmaceuticals

  • RNA interference (RNAi)-based gene silencing has become the 3rd therapeutic development platform with multiple FDA-approved RNAi drugs on market
  • Asymmetric siRNA (asiRNA) triggers efficient target gene silencing with reduced non-specific effects
  • OliX Pharmaceuticlas has developed cp-asiRNA for local administration therapeutics, and GalNAc-asiRNA for liver targeting therapeutics
  • Will describe OliX Pharmaceuticals’ pre-clinical and clinical developments against various disease indications
  • clock

    10:10

    MiRNA Therapeutics: From Bench to Bedside

    Ekkehard Leberer, Senior Director, Global Alliance Management, Sanofi

  • MicroRNAs are short non-coding RNAs that regulate biochemical pathways and networks of pathways by the mechanism of RNA interference (RNAi).
  • MicroRNA-21 has been implicated in multiple organs as a microRNA associated with fibrotic diseases and cancer.
  • We have generated an anti-fibrotic microRNA-based therapeutic approach by targeting microRNA-21 with an antisense oligonucleotide (anti-miR-21).
  • This microRNA-based drug is now in a phase 2 clinical trial for a fibrotic kidney disease called Alport Syndrome
  • clock

    10:40

    Morning Break and Virtual Exhibitor Hall Open

    clock

    11:10

    Progress in microRNA therapeutics for epilepsy and rare neurodevelopmental disorders

    Cristina Reschke, Lecturer, School of Pharmacy and Biomolecular Sciences , Royal College of Surgeons in Ireland

  • Background covering epilepsy (TLE and epilepsy as a common comorbidity in rare neurodevelopmental disorders).
  • Concepts about miRNA and functional assessments.
  • Pre-clinical journey of miR-134 inhibitor (Ant-134) in models of adult TLE
  • Pre-clinical assessment of Ant-134 in Angelman & Dravet syndromes
  • clock

    11:40

    The UK Nucleic Acid Therapy Accelerator (NATA)

  • An introduction to the aims of the NATA in supporting the development of synthetic RNA therapeutics
  • The NATA Hub: a world leading research institute to support the RNA therapeutics community, utilising dedicated capability in oligo synthesis and biological screening
  • The NATA’s upcoming funding calls to address barriers in the manufacture and the delivery of RNA therapeutics
  • Opportunities to partner with the NATA; Q&A session
  • Loic Roux, Head of Chemistry, NATA

    Tim Ellis, Programme Manager, Translational Research, Medical Research Council

    clock

    12:10

    Networking Break and Virtual Exhibitor Hall Open

    clock

    13:10

    Navigating the Intellectual Property Minefield to Protect and Optimize RNA Innovations

  • Understand how patents are managed across the innovation lifecycle to enrich and protect your valuable inventions
  • Minimize risks and optimize IP value in the increasingly crowded RNA space
  • Navigate the complexity of RNA information for quality patent searches and insights
  • Recommendations for building strong working relationships with stakeholders and partners to optimize IP value
  • Heidi M Berven, Partner, Co-Leader, Patent Practice Group, Honigman

    Matthew J McBride, Director of IP Search, CAS

    clock

    13:50

    AI Application of Drug Discovery for Triple Negative Breast Cancer

    Maria Luisa Pineda, CEO and Co-founder, Envisagenics

  • Envisagenics’ software platform, SpliceCore, integrates proprietary machine learning algorithms, high performance computing, and RNA-splicing analytics to identify disease-specific alternatively spliced RNA that will function as therapeutic targets 
  • Discovery of novel TNBC specific splicing isoforms
  • Designing optimal RNA-therapeutics targeting TNBC specific splicing isoforms using machine learning
  • Experimental qualification and validation of ASOs designed by SpliceCore
  • clock

    14:20

    RNA Nanotechnology Unlocks The Potential of Small RNA Therapeutics

    Fengmei Pi, General Manager and Director of R&D, ExonanoRNA

  • RNA nanoparticles for targeted delivery of anti-miRNA for oncology disease
  • RNA nanoparticles for targeted delivery of chemical drug for oncology disease
  • RNA nanoparticles decorated exosomes for targeted delivery of siRNA
  • Pipeline and plan
  • clock

    14:50

    Afternoon Break and Virtual Exhibitor Hall Open

    clock

    15:20

    Precision medicine to treat genetic disorders

    Barry Ticho, Chief Medical Officer, Stoke Therapeutics

  • An overview of the TANGO platform and how it works
  • Antisense oligonucleotides for targeted binding to mRNA
  • The challenge of oligonucleotides for non-liver delivery and potential applications for severe genetic diseases affecting the CNS
  • Case Study: Dravet Syndrome
  • clock

    15:50

    Panel Discussion: COVID-19: how has the RNA industry adapted to beat the pandemic

  • The global collaboration to facilitate development and evaluation of therapeutics, diagnostics and vaccines against COVID-19
  • Current mRNA vaccines in development
  • How has industry adapted clinical trials and R&D to allow accelerated development?
  • How have approval processes been accelerated and will this affect future approval processes post-pandemic?

     

  • Heinrich Haas, Vice President Formulation and Drug Delivery , BioNTech

    Troels Koch, CEO & Founder, Aqiventa

    Kirsty Wydenbach, Deputy Unit Manager/Senior Medical Assessor, MHRA

    Michael Mulqueen, VP Business Development, eTheRNA Immunotherapies

    clock

    16:30

    mRNA and developing a COVID-19 vaccine

  • An introduction to Arcturus Therapeutics 
  • mRNA technologies and the therapeutic potential
  • An overview of the LUNAR delivery technology
  • Case Study: LUNAR-COV19
  • Priya Karmali, Vice President, Technology Innovation and Development, Arcturus Therapeutics

    clock

    17:00

    Chair’s Closing Remarks

    Heinrich Haas, Vice President Formulation and Drug Delivery , BioNTech

    Shalini Andersson, Chief Scientist New Therapeutic Modalities and Head of Oligonucleotide Discovery, AstraZeneca


    CEO
    Advirna
    Chief Scientific Officer
    PCI Biotech AS
    Senior Medical Affairs Director
    Sarepta Therapeutics Germany GmbH
    Team Leader, Advanced Drug Delivery, Pharmaceutical Sciences
    Astrazeneca
    Chief Medical Officer
    Stoke Therapeutics
    Lecturer, School of Pharmacy and Biomolecular Sciences
    Royal College of Surgeons in Ireland
    Chief Scientific Officer
    Sirnaomics, Inc
    CEO
    OilX Pharmaceuticals
    Senior Director, Global Alliance Management
    Sanofi
    General Manager and Director of R&D
    ExonanoRNA
    Head, Vector Biology
    GSK Vaccines
    Partner, Co-Leader, Patent Practice Group
    Honigman
    Vice President Formulation and Drug Delivery
    BioNTech
    Vice President Medical Afffairs
    ProQR
    Marketing Manager
    Unchained Labs
    Deputy Unit Manager/Senior Medical Assessor
    MHRA
    Head of Chemistry
    NATA
    CEO and Co-founder
    Envisagenics
    Director of IP Search
    CAS
    VP Business Development
    eTheRNA Immunotherapies
    Senior Scientist
    AstraZeneca
    Senior Scientist
    AstraZeneca
    Vice President, Technology Innovation and Development
    Arcturus Therapeutics
    Senior Research Engineer, New Therapeutics Modalities
    Eli Lilly and Company
    Chief Scientist New Therapeutic Modalities and Head of Oligonucleotide Discovery
    AstraZeneca
    Director, Institute of Molecular and Translational Therapeutic Strategies
    Hannover Medical School
    Programme Manager, Translational Research
    Medical Research Council
    CEO & Founder
    Aqiventa
    CSO
    Frame Therapeutics

    Sponsors

    Exhibitors

    Supporting Media Partners

    Speaker Interview with Ruchi Shah, Eli Lilly and Company

    Download

    Preliminary Attendees List 2021

    Download

    Speaker interview with Shalini Andersson, AstraZeneca

    Download

    Speaker interview with Jennifer Pluim, ProQR

    Download

    Chair letter 2021

    Download

    RNA Therapeutics short programme 2021

    Download

    RNA Therapeutics full programme 2021

    Download

    Past Attendee List

    Download

    PAST PRESENTATION - David Blakey - Mina Therapeutics

    Download

    PAST PRESENTATION - Surender Vashist - AstraZeneca

    Download

    PAST PRESENTATION - Klaus Giese - Pantherna Therapeutics

    Download

    PAST PRESENTATION - Heinrich Haas - BioNTech

    Download

    PAST PRESENTATION - Dr. Michel Janicot - InteRNA Technologies

    Download

    PAST PRESENTATION - David. C. Henshall - Royal College of Surgeons of Ireland

    Download

    PAST PRESENTATION - Dr Kirsty Wydenbach - MHRA

    Download

    PAST PRESENTATION - Dr Simon Newman - NanoGenics

    Download

    PAST PRESENTATION - David Deutsch - MHRA

    Download

    PAST PRESENTATION - Christopher Bunker - Advanced Cell Diagnostics

    Download

    PAST PRESENTATION - Bo Rode Hansen, PhD - Genevant Sciences, Inc

    Download

    Sponsors


    CAS

    Sponsors
    http://www.cas.org/

    CAS, a division of the American Chemical Society, specializes in scientific information solutions to help R&D organizations globally plan, innovate, and protect their innovations, and predict how new markets and opportunities will evolve. Scientific researchers, intellectual property professionals and business leaders around the world across commercial, academic and government sectors rely on our solutions and services to advise discovery and strategy. Leverage our unparalleled content, specialized technology, and unmatched human expertise for solutions that will give your organization an information advantage. With more than 110 years' experience, no one knows more about scientific information than CAS.


    PCI Biotech

    Sponsors
    https://www.pcibiotech.no/

    PCI Biotech is a biopharmaceutical late stage clinical development company focusing on development and commercialisation of novel therapies for the treatment of cancer through its innovative photochemical internalisation (PCI) technology platform.

    PCI works by releasing biologically active molecules inside cells, allowing the molecules to interact with their specific biological targets in the cell. PCI does this by permeabilising endocytic vesicles in a light-induced process.

    The PCI technology can among other things be used for enhancing intracellular delivery of nucleic acids, such as mRNA and RNAi therapeutics, thereby addressing one of the major bottlenecks facing this emerging and promising field.



    Unchained Labs

    Sponsors
    http://unchainedlabs.com

    Here’s the deal. We’re all about helping researchers break free from tools that just don’t cut it. Unleashing problem-tackling products that make a huge difference in the real science they do every day. That’s our mantra, our promise and we own it.

    Exhibitors


    eTheRNA immunotherapies NV

    Exhibitors
    http://www.etherna.be

    eTheRNA immunotherapies is a clinical-stage company delivering innovative cancer immunotherapies from its proprietary mRNA-based TriMix platform. eTheRNA’s goal is to commercialise these immunotherapies to deliver long lasting clinical remission to cancer patients. eTheRNA was established in January 2013 as a spin-off from the VUB university in Belgium and is backed by international life sciences investors.


    Thermo Fisher Scientific

    Exhibitors
    http://www.thermofisher.com/

    As a worldwide leader in serving science, Thermo Fisher Scientific invites you to partner with us to reach your RNA therapeutic development goals. Explore our portfolio of high-quality TheraPure reagents designed for your oligonucleotide and mRNA synthesis to help you move your project from development to manufacturing and commercialization. Accelerate your productivity and innovation with expertise, services, and support from Thermo Fisher Scientific.

    Media Partners


    pharmaphorum

    Supporting Media Partners
    http://www.pharmaphorum.com

    pharmaphorum drives innovation within the pharmaceutical industry, by bringing healthcare together through a suite of media services that help produce and disseminate thought leadership, combined with an online platform for communicating messages to a global audience.Visit www.pharmaphorum.com


    ASD MEDIA

    Supporting Media Partners
    http://www.asd-network.com

    Professionals in the Aerospace & Defence market use the ASD Media internet platforms to:
    • Be informed on the latest market developments; www.asd-network.com
    • Find the latest business news; www.asd-network.com
    • Find the upcoming events; www.asd-network.com
    • Find companies and organizations; www.asdsource.com
    • Distribute news globally. www.asdwire.com
    The ASD Media platforms are well known and used intensively, your company is able to benefit from these large numbers of users. Be informed with ASD-Network; Create exposure for your company with ASDSource, distribute your news with ASDWire or advertise with us, build your brand and increase traffic to your company’s website.

    For more detailed information please contact with: ASD MEDIA
    Stefan.koopman@asdmedia.nl


    Gene Therapy Net

    Supporting Media Partners
    http://www.genetherapynet.com

    Gene Therapy Net is the information resource for basic and clinical research in gene therapy, and the site serves as a network in the exchange of gene therapy information and breaking news items. Visitors can keep track of the latest scientific papers, conference announcements, gene therapy jobs, regulations and guidelines


    The Medicine Maker

    Supporting Media Partners
    https://themedicinemaker.com/?utm_source=media_partner_24&utm_medium=event&utm_campaign=sae_media_logo

    The Medicine Maker is a print and digital publication as well as a weekly newsletter. At The Medicine Maker, we bring people into the limelight, showcasing the industry’s success stories and examining its biggest points of contention. Engaging content covers the entire spectrum of drug development, keeping all medicine makers up to date with the most pressing topics, trends and technologies driving the pharma industry forward. Register for your FREE print or digital magazine or subscribe to our newsletter here! https://themedicinemaker.com/?utm_source=media_partner_24&utm_medium=event&utm_campaign=sae_media_logo


    pharmanews hq

    Supporting Media Partners
    http://http://pharmanewshq.com

    MedChemNet provides a unique and unparalleled platform for the medicinal chemistry community to share insights, discuss the latest research, and help move the field forward. MedChemNet covers all aspects of the drug discovery pipeline, from target identification and validation, through computer aided drug design (CADD), synthesis, screening and other biophysical techniques, to development of novel lead compounds and pre-clinical in vivo proof of concept. We also cover the design of synthetic drug delivery carriers and ADME/toxicology studies, as well as intellectual property and economic related issues. Website: Welcome to Pharma News HQ, the journal dedicated to the pharmaceutical and biopharmaceutical contract services. With regular sections on contract manufacturing, contract research, contract packaging, formulation/development services, contract analytical testing, APIs, stability testing, clinical research and other areas, we bring the most complete coverage of trends and issues in the industry. Pharmanewshq.com is the only website focusing specifically on issues relevant to pharmaceutical professionals working with technology, be it development, engineering, IT or production.


    Pharmacircle

    Supporting Media Partners
    http://www.pharmacircle.com

    PharmaCircle is an innovative knowledge management company serving the current and future global leaders in the Pharmaceutical and Biotechnology related industries. PharmaCircle is a one stop information and analysis source for pipeline, products, clinical trials, drug delivery technologies, deals and acquisitions, company financials, venture capital investments, product sales, pharmaceutical services, news, patents and more….


    Technology Networks

    Supporting Media Partners
    http://go.technologynetworks.com/subscribe-to-newsletters

    Founded in 2000, Technology Networks is established as the leading news provider for life science and drug discovery professionals. In addition, we provide unique content including webcasts, videos, application notes and posters from recent conferences. Our portfolio now includes around 30 focussed scientific communities, all of which are accessible free of charge within TechnologyNetworks.com


    Mednous

    Supporting Media Partners
    http://www.MedNous.com

    MedNous is a print publication and website about medical innovation in Europe. It carries exclusive interviews with companies that are at the forefront of medical technology, as well as contributor articles from prominent practitioners. Our mission is to identify significant advances in medicine and to explain how this innovation is being commercialised. In doing so, we talk to venture capitalists about what products and platforms they are supporting. We report on how regulators cope with the accelerating pace of innovation. And we regularly cover the latest developments in the discovery and development of new medical concepts in the area of antibodies, vaccines, small molecules, regenerative medicine and nanomedicines. MedNous combines the English word for medicine with the Greek word for intellect. And those with nous are readers of our publication. Visit our website: www.mednous.com


    Drug Discovery Today

    Supporting Media Partners
    http://www.drugdiscoverytoday.com/

    Drug Discovery Today covers the whole of the preclinical drug discovery process. The reviews are cutting edge, written by experts in their respective fields and cover all aspects of drug discovery from genomic and proteomic approaches, computational drug design, medicinal chemistry and the translation of these sciences to therapies.


    Pharmalicensing

    Supporting Media Partners
    http://www.pharmalicensing.com

    Pharmalicensing (www.pharmalicensing.com) is the premier biopharmaceutical Open Innovation resource designed for professionals involved with partnering, licensing and business development worldwide. Actively supporting all forms of partnering and in- and out-licensing activities, Pharmalicensing utilizes the unique online Showcase Profiling & Discover services, as well as its renowned Partnering Search service leveraging its global network of industry experts, to enable companies to identify and engage with appropriate partners around the world. Pharmalicensing is actively utilized by many tens of thousands of industry professionals each month. Pharmalicensing is a division of Cognis Group, Inc.


    Pharmavision

    Supporting Media Partners
    http://www.pharmavision.co.uk

    PharmaVision offers a consultancy service providing independent pharmaceutical thematic research to the healthcare industry, the investment community and competitive intelligence specialists. We perform due diligence research and provide expert commentary in healthcare. Our reports combine scientific analysis in drug delivery, R&D technologies and pharmaceutical products including patient modelling, product/technology forecasts and market trends evaluation.


    Farmavita

    Supporting Media Partners
    https://farmavitar.com

    FarmavitaR+ is the professional network of experts and service providers. Network is gathering local consultants from 90 countries in Europe, Asia, North America, Latin America, Australia and Africa. Management of international, multi-centre projects is our core competence. FarmavitaR+ is providing solutions related to pharmaceutical, medical device, food supplement and cosmetic products. Scope of services is related to solutions for product development, quality assurance, clinical trials, product registration, portfolio analysis, lifecycle management, vigilance/risk management, pricing/reimbursing, market access and promotional compliance. FarmavitaR+ is brand name of Farmavita Regulanet Ltd. Visit https://farmavitar.com for more information. Outsource anything you can think of!


    Pharma Journalist

    Supporting Media Partners
    http://www.pharmajournalist.com

    Pharma Journalist is a product of Kellen Media. Pharma Journalist is one of the leading website covering the need of global Pharmaceutical Industry. Articles like latest news, trends, analysis, market report, press releases, whitepapers, case studies, etc. published on pharmajournalist.com helps Industry professionals and decision makers to stay on the top of this fast-paced industry. Pharma Journalist aims of providing fast and informative articles to its readers and subscribers.

    Online Virtual Event

    Online Virtual Event
    United Kingdom

    Online Virtual Event

    HOTEL BOOKING FORM

    Title

    SubTitle
    speaker image

    Content


    Title


    Description

    Download

    Title


    Description

    Download

    Title


    Description


    Download


    WHAT IS CPD?

    CPD stands for Continuing Professional Development’. It is essentially a philosophy, which maintains that in order to be effective, learning should be organised and structured. The most common definition is:

    ‘A commitment to structured skills and knowledge enhancement for Personal or Professional competence’

    CPD is a common requirement of individual membership with professional bodies and Institutes. Increasingly, employers also expect their staff to undertake regular CPD activities.

    Undertaken over a period of time, CPD ensures that educational qualifications do not become obsolete, and allows for best practice and professional standards to be upheld.

    CPD can be undertaken through a variety of learning activities including instructor led training courses, seminars and conferences, e:learning modules or structured reading.

    CPD AND PROFESSIONAL INSTITUTES

    There are approximately 470 institutes in the UK across all industry sectors, with a collective membership of circa 4 million professionals, and they all expect their members to undertake CPD.

    For some institutes undertaking CPD is mandatory e.g. accountancy and law, and linked to a licence to practice, for others it’s obligatory. By ensuring that their members undertake CPD, the professional bodies seek to ensure that professional standards, legislative awareness and ethical practices are maintained.

    CPD Schemes often run over the period of a year and the institutes generally provide online tools for their members to record and reflect on their CPD activities.

    TYPICAL CPD SCHEMES AND RECORDING OF CPD (CPD points and hours)

    Professional bodies and Institutes CPD schemes are either structured as ‘Input’ or ‘Output’ based.

    ‘Input’ based schemes list a precise number of CPD hours that individuals must achieve within a given time period. These schemes can also use different ‘currencies’ such as points, merits, units or credits, where an individual must accumulate the number required. These currencies are usually based on time i.e. 1 CPD point = 1 hour of learning.

    ‘Output’ based schemes are learner centred. They require individuals to set learning goals that align to professional competencies, or personal development objectives. These schemes also list different ways to achieve the learning goals e.g. training courses, seminars or e:learning, which enables an individual to complete their CPD through their preferred mode of learning.

    The majority of Input and Output based schemes actively encourage individuals to seek appropriate CPD activities independently.

    As a formal provider of CPD certified activities, SAE Media Group can provide an indication of the learning benefit gained and the typical completion. However, it is ultimately the responsibility of the delegate to evaluate their learning, and record it correctly in line with their professional body’s or employers requirements.

    GLOBAL CPD

    Increasingly, international and emerging markets are ‘professionalising’ their workforces and looking to the UK to benchmark educational standards. The undertaking of CPD is now increasingly expected of any individual employed within today’s global marketplace.

    CPD Certificates

    We can provide a certificate for all our accredited events. To request a CPD certificate for a conference , workshop, master classes you have attended please email events@saemediagroup.com

    Event Title

    Headline

    Text
    Read More

    I would like to speak at an event

    I would like to attend an event

    Group Booking

    Please complete the below form and a member of SAE Media Group’s booking team will be in contact within 24 hours

    I would like to sponsor/exhibit at an event

    SIGN UP OR LOGIN

    Sign up
    Forgotten Password?

    Contact SAE Media Group

    UK Office
    Opening Hours: 9.00 - 17.30 (local time)
    SAE Media Group , Ground Floor, India House, 45 Curlew Street, London, SE1 2ND, United Kingdom
    Tel: +44 (0) 20 7827 6000 Fax: +44 (0) 20 7827 6001
    Website: http://www.smgconferences.com Email: events@saemediagroup.com
    Registered in England - SMi Group Ltd trading as SAE Media Group




    Forgotten Password

    Please enter the email address you registered with. We will email you a new password.

    Thank you for visiting our event

    If you would like to receive further information about our events, please fill out the information below.

    By ticking above you are consenting to receive information by email from SAE Media Group.
    Full details of our privacy policy can be found here https://www.smgconferences.com/privacy-legals/privacy-policy/.
    Should you wish to update your contact preferences at any time you can contact us at data.privacy@smgconferences.com.
    Should you wish to be removed from any future mailing lists please click on the following link http://www.smgconferences.com/opt-out

    Fill in your details to download the brochure

    By submitting this form you agree to our privacy policy and consent to receiving communications, you may opt out at any time.